Search results for "TCO"

showing 10 items of 5331 documents

Diagnostic genetic screening for assisted reproductive technologies patients with macrozoospermia

2017

International audience; Macrozoospermia is characterized by a high proportion of abnormal spermatozoa with enlarged heads. So far, it has been associated with mutations only in the Aurora Kinase C gene (AURKC) in some cases. Although many publications have reported failure to conceive in couples with macrozoospermia, a few others have described successful pregnancies, thus raising questions as to whether ICSI and AURKC genetic screening should be recommended in all patients with macrozoospermia. First, we report on two monozygotic twins presenting macrozoospermia for whom the genetic status was explored (Aurora Kinase C sequencing) and whole semen and gradient-selected spermatozoa were anal…

AdultMale0301 basic medicineReproductive Techniques Assistedpregnancy outcomesUrologyEndocrinology Diabetes and MetabolismTwinsmenSemenReproductive technologyBiologymedicine.disease_causeAndrologyTeratozoospermia03 medical and health sciences0302 clinical medicineEndocrinologyPolyploidc c.144delc mutationmedicineHumansAurora Kinase CGenetic TestingAurora Kinase C Gene[SDV.GEN]Life Sciences [q-bio]/Geneticsaurora kinase C geneMutationassisted reproductive technologies030219 obstetrics & reproductive medicineurogenital systemtailed spermatozoaGenetic StatusheadSperm3. Good healthmacrozoospermiahuman sperm030104 developmental biologyReproductive Medicinemale-infertilitySperm HeadAurora Kinase Caneuploidy rateflow-cytometry[ SDV.GEN ] Life Sciences [q-bio]/Geneticspolyploid spermatozoaAndrology
researchProduct

Evaluation of the effect of an intervention on the nutritional status of hospitalized patients

2017

Abstract Background and objectives To compare the nutritional status of a population of hospitalized patients, divided into 2 different groups, both at admission and hospital discharge, and to assess the influence of nutritional alteration during the hospital stay. Material and methods Quasi-experimental study comprising 2 groups of patients (N = 581): an intervention group (n = 303), in which nurses received specific training on managing care methodology, and a control group (n = 278), in which nurses continued their usual dynamics. Each group was made up of 2 care units with patients from both surgical and medical specialties. Inclusion criteria: patients admitted to the selected units wi…

AdultMale0301 basic medicineSample selectionPediatricsmedicine.medical_specialtyHospitalized patientsPopulationNutritional Status03 medical and health sciences0302 clinical medicinePatient ageIntervention (counseling)Hospital dischargeHumansMedicineProspective Studies030212 general & internal medicineeducationAgedAged 80 and overeducation.field_of_study030109 nutrition & dieteticsbusiness.industryMalnutritionNutritional statusOdds ratioMiddle AgedHospitalizationNutrition AssessmentTreatment OutcomeFemaleNutrition TherapybusinessFollow-Up StudiesMedicina Clínica (English Edition)
researchProduct

Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS

2017

Background: The effect of dimethyl fumarate (DMF) on circulating lymphocyte subsets and their contribution as predictors of clinical efficacy have not yet been investigated in multiple sclerosis (MS). Objective: To evaluate lymphocytes and lymphocyte subsets (analyzed 6 months after DMF start) in MS patients with and without disease activity after 1 year of treatment in a retrospective study. Methods: Peripheral blood lymphocyte subsets were analyzed by flow cytometry. Untreated MS patients ( n = 40) were compared to those 6 months after onset of DMF treatment ( n = 51). Clinical and magnetic resonance imaging (MRI) disease activity of DMF-treated patients were assessed in the first year un…

AdultMale0301 basic medicineTreatment responseMultiple SclerosisAdolescentDimethyl FumarateAntigens CD19CD4-CD8 RatioCD8-Positive T-LymphocytesPharmacologyStatistics NonparametricReduction (complexity)Young Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineText miningLymphopeniamedicineHumansCytotoxic T cellLongitudinal StudiesLymphocyte CountClinical efficacyRetrospective StudiesB-LymphocytesDimethyl fumarateChemistrybusiness.industryMultiple sclerosisMiddle AgedFlow Cytometrymedicine.diseaseMagnetic Resonance ImagingCross-Sectional StudiesTreatment Outcome030104 developmental biologyROC CurveNeurologyDisease ProgressionFemaleNeurology (clinical)businessImmunosuppressive Agents030217 neurology & neurosurgeryFollow-Up StudiesLymphocyte subsetsMultiple Sclerosis Journal
researchProduct

Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis

2015

Background and purpose: Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid that is produced in the liver and used for treatment of chronic cholestatic liver diseases. Experimental studies suggest that TUDCA may have cytoprotective and anti-apoptotic action, with potential neuroprotective activity. A proof of principle approach was adopted to provide preliminary data regarding the efficacy and tolerability of TUDCA in a series of patients with amyotrophic lateral sclerosis (ALS). Methods: As a proof of principle, using a double-blind placebo controlled design, 34 ALS patients under treatment with riluzole who were randomized to placebo or TUDCA (1 g twice daily for 54 weeks) were e…

AdultMale0301 basic medicineamyotrophic lateral sclerosismedicine.medical_specialtyALS - TUDCA - clinical trialmedicine.drug_classPilot ProjectsAmyotrophic lateral sclerosis; Cholic acids; Tauroursodeoxycholic acid; Adult; Aged; Amyotrophic Lateral Sclerosis; Double-Blind Method; Drug Therapy Combination; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Pilot Projects; Riluzole; Taurochenodeoxycholic Acid; Outcome Assessment (Health Care); Neurology; Neurology (clinical)PlaceboNeuroprotectionGastroenterologyTaurochenodeoxycholic AcidOutcome Assessment (Health Care)03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodDrug TherapyInternal medicinemedicineCholic acidHumansAmyotrophic lateral sclerosisAdverse effectAmyotrophic lateral sclerosiAgedtauroursodeoxycholic acidRiluzoleBile acidbusiness.industryTauroursodeoxycholic acidMiddle Agedmedicine.diseaseRiluzoleSurgerySettore MED/26 - NEUROLOGIANeuroprotective Agentscholic acids030104 developmental biologyNeurologychemistryTolerabilityCombinationFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugEuropean Journal of Neurology
researchProduct

Corneal confocal scanning laser microscopy in patients with dry eye disease treated with topical cyclosporine

2017

Purpose To investigate the effect of cyclosporine on corneal ultrastructure and on major signs and symptoms of patients with dry eye disease.Patients and methods In this prospective cohort study, patients with dry eye disease were treated with a drop of cyclosporine 0.05% twice daily. Clinical evaluation was carried out at baseline and at months 1, 3, and 6. All patients completed the Ocular Surface Disease Index (OSDI) questionnaire, and tear film break-up time (BUT), fluorescein and lissamine green staining, and Schirmer test were carried out. In vivo confocal microscopy was also performed and epithelial cellular density, keratocyte activation, and subbasal plexus morphology were assessed…

AdultMale0301 basic medicinemedicine.medical_specialtyAdministration TopicalConfocalDry Eye SyndromesGlaucomaCell CountOphthalmic SolutionFollow-Up StudieCorneaImmunosuppressive Agent03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOphthalmologyCorneamedicineOcular Surface Disease IndexFluoresceinProspective cohort studyAgedMicroscopy Confocalbusiness.industryMiddle Agedmedicine.diseaseStainingProspective StudieOphthalmologyTreatment Outcome030104 developmental biologymedicine.anatomical_structureNerve FiberchemistryCyclosporine030221 ophthalmology & optometryFemalebusinessDry Eye SyndromeHumanEye
researchProduct

A manual therapy and home stretching program in patients with primary frozen shoulder contracture syndrome : a case series

2019

Abstract: Background Manual therapy has been demonstrated to reduce pain and improve function in patients with frozen shoulder contracture syndrome (FSCS), but no evidence exists to support one form of manual therapy over another. The purpose of this case series was to describe both short and long-term outcomes after a manual therapy program and home stretching exercises based on specific impairments in shoulder mobility and level of tissue irritability in patients with FSCS. Case Description Eleven patients with primary FSCS were treated with an individually tailored multimodal manual therapy approach once weekly for 12 visits coupled with home stretching exercises once a day, five days pe…

AdultMale0301 basic medicinemedicine.medical_specialtyEconomicsPainMobilizationPhysical Therapy Sports Therapy and RehabilitationCASE SERIES03 medical and health sciences0302 clinical medicineSociologyBursitisShoulder PainMuscle Stretching ExercisesmedicineHumansIn patientMuscle StrengthRange of Motion Articularbusiness.industryFrozen shoulderFrozen shoulderGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyMusculoskeletal ManipulationsSurgeryTreatment Outcome030104 developmental biologymanipulationFemaleSelf ReportHuman medicineContracturemedicine.symptomManual therapybusiness030217 neurology & neurosurgeryJournal of orthopaedic & sports physical therapy
researchProduct

Application of tRNS to improve multiple sclerosis fatigue: a pilot, single-blind, sham-controlled study

2019

We evaluated the effects of transcranial random noise stimulation (tRNS) on fatigue in 17 subjects with relapsing–remitting multiple sclerosis with low physical disability. Two different patient groups underwent real or sham stimulation for 10 days, targeting the primary motor cortex of the dominant side or contralateral to the most compromised limb. In the ‘real group’, beneficial effects were observed using the Modified Fatigue Impact Scale (p = 0.04; physical subscale: p = 0.03), the subscales ‘change in health’ (p = 0.006) and ‘role limitations due to physical problems’ (p = 0.001) of the Multiple Sclerosis Quality of Life-54, and by assessing the patient impression of perceived fatigue…

AdultMale0301 basic medicinemedicine.medical_specialtyPhysical disabilityNeurologyFatigue treatmentStimulationTranscranial Direct Current StimulationSeverity of Illness IndexPlacebosYoung Adult03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicinePhysical medicine and rehabilitationOutcome Assessment Health CaremedicineHumansMultiple sclerosiSingle-Blind MethodBeneficial effectsFatigueBiological Psychiatrybusiness.industryMSQoL-54Multiple sclerosisMotor CortextRNSmedicine.diseaseFatigue impact scalePsychiatry and Mental health030104 developmental biologyPrimary motor areaNeurologyQuality of LifeFemaleMFISNeurology (clinical)Single blindPrimary motor cortexbusiness030217 neurology & neurosurgeryJournal of Neural Transmission
researchProduct

Aluminum Chloride versus Electrocauterization in Periapical Surgery: A Randomized Controlled Trial

2019

The aim of this study was to evaluate the efficacy of 2 hemostatic agents in periapical surgery and its relationship with patient- and tooth-dependent variables.A prospective study was designed with 2 randomized parallel groups established according to the hemostatic agent used: aluminum chloride or electrocauterization. The surgeon and 2 independent blinded observers examined the initial and final bleeding and recorded it as 0 (no hemorrhage control), 1 (slight but apparent intermittent bleeding), or 2 (complete hemorrhage control). The following patient- and tooth-dependent variables were collected: sex, age, smoking habit, plaque index, and position.Sixty patients with a periapical lesio…

AdultMale0301 basic medicinemedicine.medical_specialtyPlaque indexHemostaticsEndodonticslaw.invention03 medical and health sciencesSex Factors0302 clinical medicineRandomized controlled triallawFemale patientElectrocoagulationmedicineAluminum ChlorideHumansProspective StudiesProspective cohort studyGeneral Dentistrybusiness.industryPeriapical Diseases030206 dentistryMiddle AgedHemostasis SurgicalSurgeryTreatment Outcome030104 developmental biologyMale patientHemorrhage controlFemaleElectrocauterizationbusinessPeriapical surgeryJournal of Endodontics
researchProduct

Lomitapide affects HDL composition and function

2016

Abstract Background Lomitapide reduces low-density lipoprotein-cholesterol (LDL-C) but also high-density lipoprotein-cholesterol (HDL-C) levels. The latter may reduce the clinical efficacy of lomitapide. We investigated the effect of lomitapide on HDL-C levels and on cholesterol efflux capacity (CEC) of HDL in patients with homozygous familial hypercholesterolemia (HoFH). Methods and results Four HoFH patients were treated with increasing dosages of lomitapide. Lomitapide decreased LDL-C (range −34 to −89%). Total HDL-C levels decreased (range −16 to −34%) with a shift to buoyant HDL. ABCA1-mediated CEC decreased in all patients (range −39 to −99%). The changes of total, ABCG1- and SR-BI-me…

AdultMale0301 basic medicinemedicine.medical_specialtySettore MED/09 - Medicina InternaHDLHomozygous familial hypercholesterolemiaFamilial hypercholesterolemia030204 cardiovascular system & hematologyHyperlipoproteinemia Type IIYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineHumansMedicineIn patientClinical efficacyHyperlipoproteinemia Type IICholesterolbusiness.industryCholesterol HDLHomozygotenutritional and metabolic diseasesCholesterol LDLCholesterol efflux capacityAtherosclerosismedicine.diseaseCholesterol lowering drugsLomitapideLomitapideCholesterolPhenotypeTreatment Outcome030104 developmental biologyEndocrinologychemistryBenzimidazolesFemalelipids (amino acids peptides and proteins)Composition (visual arts)Cholesterol lowering drugHydroxymethylglutaryl-CoA Reductase InhibitorsLipoproteins HDLCardiology and Cardiovascular MedicinebusinessATP Binding Cassette Transporter 1Atherosclerosis
researchProduct

Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before an…

2020

Rossella Parini,1,2 Guillem Pintos-Morell,3 Julia B Hennermann,4 Ting-Rong Hsu,5 Nesrin Karabul,6 Vasiliki Kalampoki,7 Andrey Gurevich,7 Uma Ramaswami8 On behalf of the FOS Study Group1Rare Metabolic Diseases Unit, MBBM Foundation, San Gerardo Hospital, Reference Centre for Hereditary Metabolic Disorders (MetabERN), Monza, Italy; 2TIGET Institute, IRCCS San Raffaele Hospital, Milan, Italy; 3Division of Rare Diseases, Reference Centre for Hereditary Metabolic Disorders (MetabERN), University Hospital Vall d’Hebron, Autonomous University of Barcelona, Barcelona, Spain; 4Villa Metabolica, Department of Pediatric and Adolescent Medicine, University Medical Center, Mainz, Germany; 5Dep…

AdultMale0301 basic medicinemedicine.medical_specialtyestimated glomerular filtration rateAdolescentPharmaceutical ScienceRenal functionLeft ventricular hypertrophyFabry Outcome SurveyYoung Adult03 medical and health sciences0302 clinical medicineInternal medicineDrug DiscoverymedicineHumansEnzyme Replacement TherapyEstimated glomerular filtration rateChildAgalsidase alfaOriginal ResearchRetrospective StudiesPharmacologyagalsidase alfaFabry diseaseProteinuriaDrug Design Development and Therapybusiness.industryLeft ventricular hypertrophyEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry diseaseRecombinant Proteinsleft ventricular hypertrophyIsoenzymesTreatment Outcome030104 developmental biologyMale patientalpha-Galactosidase030220 oncology & carcinogenesisEnzyme replacement therapyCohortmedicine.symptombusinessAgalsidase alfa
researchProduct